Luxturna

Luxturna (Voretigene Neparvovec) is a gene therapy designed for treating inherited retinal diseases. This innovative treatment targets specific genetic mutations to potentially restore vision.

Luxturna is used for the treatment of inherited retinal dystrophy caused by mutations in the RPE65 gene. This condition leads to progressive vision loss. Luxturna aims to address the underlying genetic cause of the disease, offering a potential solution for those affected by this rare condition.

Luxturna works by delivering a functional copy of the RPE65 gene to the retinal cells. This process aims to restore vision in individuals with this specific genetic mutation. The effects of Luxturna can vary, and patients should consult their healthcare provider for personalized information.

Luxturna is administered via subretinal injection, which is a complex procedure. It is important to discuss potential risks and benefits with a healthcare professional. Patients should also be aware of any allergies or sensitivities to the components of the therapy.

As with any medical treatment, interactions with other medications or therapies should be considered. Patients should inform their healthcare provider about all current medications and treatments before undergoing Luxturna therapy.